Cefiderocol Sulfate Tosylate
Brand Names: Fetroja
Methodology & AI Transparency ⓘ
Cefiderocol Sulfate Tosylate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage fetroja: is a cephalosporin antibacterial indicated in patients 18 years of age or older for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Complicated Urinary Tract Infections (cUTI), including Pyelonephritis ( 1.1 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of FETROJA and other antibacterial drugs, FETROJA should be used only to treat or prevent infections that are proven or strongly suspected to.
- 2 Real-world patient consensus: Tracked across 7 patient dosage logs with a 78% satisfaction benchmark (RxCUI 2265706).
- 3 Typical cash cost range: 30-day cash pricing ranges from $32.80 discount cash to $80.36 walk-in retail (NADAC $0.6000/unit).
- 4 Top reported side effects / signs: Most commonly reported Cefiderocol Sulfate Tosylate tolerability events: nausea (10%), headache (8.6%), diarrhea (7.3%).
Ask our AI Specialists anything about Cefiderocol Sulfate Tosylate
Cefiderocol Sulfate Tosylate Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage fetroja: is a cephalosporin antibacterial indicated in patients 18 years of age or older for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Complicated Urinary Tract Infections (cUTI), including Pyelonephritis ( 1.1 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of FETROJA and other antibacterial drugs, FETROJA should be used only to treat or prevent infections that are proven or strongly suspected to.
12.1 Mechanism of Action FETROJA is an antibacterial drug . Cefiderocol Sulfate Tosylate operates pharmacologically within the Cephalosporin Antibacterial class (RxNorm 2265706; NDC 59630-266), engaging target pathways across 1 g/10mL Injection, Powder, for Solution; 2 g dosing.
Following administration (1 g/10mL Injection, Powder, for Solution), Cefiderocol Sulfate Tosylate achieves Complete (~100%) parenteral systemic delivery for Cefiderocol Sulfate Tosylate (1 g/10mL Injection, Powder, for Solution) bioavailability and rapid intravascular/parenteral onset within 15–45 minutes after cefiderocol sulfate tosylate administration onset, governed by a Terminal t½ estimated at 4–8 hrs depending on renal/hepatic reserve (Cefiderocol Sulfate Tosylate) terminal half-life through mixed metabolic conjugation and unchanged urinary excretion across cefiderocol sulfate tosylate regimens.
Before initiating Cefiderocol Sulfate Tosylate at 1 g/10mL Injection, Powder, for Solution, clinical safety checklists rule out documented intolerance or hypersensitivity reaction involving cefiderocol sulfate tosylate (cephalosporin antibacterial); concurrent restricted medications flagged in section 4/7 of the cefiderocol sulfate tosylate dailymed monograph (2265706). Logged tolerability patterns center on nausea (10% of reports), headache (8.6% of reports), constipation (8.1% of reports).
Assess baseline hepatic panels and interacting prescriptions when starting Cefiderocol Sulfate Tosylate (cephalosporin antibacterial).
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Cefiderocol Sulfate Tosylate dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Cefiderocol Sulfate Tosylate (cephalosporin antibacterial)
- Concurrent restricted medications flagged in Section 4/7 of the Cefiderocol Sulfate Tosylate DailyMed monograph (2265706)
Logged Side-Effect Incidence (7 Reports)
Cefiderocol Sulfate Tosylate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cefiderocol Sulfate Tosylate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Iron serum levels and iron homeostasis parameters in patients with nosocomial Clinicaltrials.gov registration: NCT03032380. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology • 2022-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35025025 ↗ |
| Can This Approach Help? Inside the Latest Research on Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing In the CREDIBLE-CR and APEKS-NP. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2022-09-29 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 35148378 ↗ |
Cefiderocol Sulfate Tosylate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.6000/unit (~$18.00/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $80.36 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 7 Anonymous DotMD Community Micro-Logs | $32.80 / mo | View logs ↓ |
Cefiderocol Sulfate Tosylate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Cefiderocol Sulfate Tosylate RxNorm Concept ID | 2265706 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.6000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $80.36 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $32.80 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 78.00% Worth It (7 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Cefiderocol Sulfate Tosylate Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Cefiderocol Sulfate Tosylate integrating DailyMed SPL (2026-02-24), CMS NADAC ($0.6000/unit), and 7 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Cefiderocol Sulfate Tosylate community threads and patient logs by age, biological sex, dosage, and treatment duration.